Page last updated: 2024-12-06

miramistin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

miramistin: do not confuse with alkamides [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	72949
CHEMBL ID	4650346
SCHEMBL ID	2236560
MeSH ID	M0162089

Synonyms (37)

Synonym
miramistin
myramistin
miramystin
126338-77-0
15809-19-5
benzyldimethyl(3-tetradecamidopropyl)ammonium chloride
ammonium, benzyldimethyl(3-myristamidopropyl)-, chloride
dt 2 (surfactant)
benzyldimethyl(3-((1-oxotetradecyl)amino)propyl)ammonium chloride
unii-ql5j8f55lh
einecs 239-908-9
benzenemethanaminium, n,n-dimethyl-n-(3-((1-oxotetradecyl)amino)propyl)-, chloride
ql5j8f55lh ,
SCHEMBL2236560
miramistin [who-dd]
benzenemethanaminium, n,n-dimethyl-n-(3-((1-oxotetradecyl)amino)propyl)-, chloride (1:1)
benzyldimethyl(3-myristoylamino)propyl) ammonium chloride
miramistin [mart.]
dt 2
AKOS030524146
D71059
benzyldimethyl[3-[(1-oxotetradecyl)amino]propyl]ammonium chloride
myristamidopropyldimethylbenzylammonium chloride
c26h47cln2o
DTXSID20925509
Q4295526
DS-19584
n-benzyl-n,n-dimethyl-3-tetradecanamidopropan-1-aminium chloride
benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride
n-benzyl-n,n-dimethyl-3-tetradecanamidopropan-1-aminiumchloride
myramistin;miramistin
BCP26374
CHEMBL4650346
CS-0029304
benzyldimethyl(3-tetradecanamidopropyl)azanium chloride
EN300-26515790
Z3247509968

Research Excerpts

Overview

Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms and a clinical profile showing good tolerability. It was developed in the Soviet Union during the Cold War.

Excerpt	Reference	Relevance
"Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms and a clinical profile showing good tolerability. "	( The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. Denning, DW; Farooq, Z; Osmanov, A; Richardson, MD, 2020)	2.35
"Miramistin is a topical antiseptic with broad antimicrobial activity that was developed in the Soviet Union during the Cold War."	( In vitro and in vivo efficacy of miramistin against drug-resistant fungi. Denning, DW; Osmanov, A; Wise, A, 2019)	2.24

Treatment

Excerpt	Reference	Relevance
"Treatment with Miramistin inhibited biofilm formation by 2-3 times compared to the control."	( Effects of Miramistin and Phosprenil on Microbial Biofilms. Adzhieva, AA; Danilina, GA; Danilova, TA; Minko, AG; Nikolaeva, TN; Pronin, AV; Zhukhovitskii, VG, 2017)	1.18

Compound-Compound Interactions

Excerpt	Reference	Relevance
"Experience of clinical treatment of 9 patients with diabetes mellitus and diabetic angiopathy using alprostan in combination with rays "Bioptron-II" and iruxol-miramistinum in conditions of polyclinic was summarized."	( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis]. Tomashuk, II; Tomashuk, IP, 2001)	0.73

Dosage Studied

Excerpt	Relevance	Reference
"1 mg dosage in 150-200 ml isotonic solution of sodium chloride during 15 days."	( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis]. Tomashuk, II; Tomashuk, IP, 2001)	0.54

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (67)

Assay ID	Title	Year	Journal	Article
AID1684364	Antibacterial activity against methicillin- resistant Staphylococcus intermedius 1143 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761373	Antibacterial activity against clinical isolate Serratia marcescens 1966 measured after 24 hrs by broth microdilution method
AID1684355	Antibacterial activity against methicillin- resistant Pseudomonas spp. clinical isolate 6 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684398	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684369	Selectivity index, ratio of CC50 for human HSF cells to MIC for Klebsiella pneumoniae ATCC 1813	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761358	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus intermedius 1061 measured after 24 hrs by broth microdilution method
AID1761356	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 983 measured after 24 hrs by broth microdilution method
AID1761364	Antibacterial activity against clinical isolate Enterococcus faecalis 3063 measured after 24 hrs by broth microdilution method
AID1684362	Antibacterial activity against methicillin- resistant Staphylococcus aureus 25 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684374	Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761379	Antibacterial activity against Escherichia coli assessed as fold increase in MIC after 4 passages by serial dilution method
AID1761340	Antibacterial activity against Escherichia coli MG 1655 measured after 24 hrs by broth microdilution method
AID1761343	Cytotoxicity against human mesenchymal stem cells assessed as cell viability measured after 72 hrs by MTT assay
AID1761362	Antibacterial activity against clinical isolate Staphylococcus aureus 25 measured after 24 hrs by broth microdilution method
AID1684379	Bactericidal activity against Staphylococcus epidermidis assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684372	Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus epidermidis	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684391	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684366	Antibacterial activity against methicillin- resistant Staphylococcus aureus 967 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761337	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 24 hrs by broth microdilution method
AID1761371	Antibacterial activity against clinical isolate Klebsiella pneumoniae 1813 measured after 24 hrs by broth microdilution method
AID1684394	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684352	Antibacterial activity against methicillin- resistant Proteus sp. clinical isolate 17 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684354	Antibacterial activity against methicillin- resistant Klebsiella sp. clinical isolate 11 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761372	Antibacterial activity against clinical isolate Pseudomonas aeruginosa 1945 measured after 24 hrs by broth microdilution method
AID1761385	Acute toxicity in po dosed C57BL/6CBA mouse measured upto 7 days
AID1684357	Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 3 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684353	Antibacterial activity against methicillin- resistant Klebsiella sp. clinical isolate 12 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761342	Cytotoxicity against human HEK293 cells assessed as cell viability measured after 72 hrs by MTT assay
AID1761363	Antibacterial activity against clinical isolate Enterococcus faecalis 23 measured after 24 hrs by broth microdilution method
AID1761366	Antibacterial activity against clinical isolate Pseudomonas sp. 5 measured after 24 hrs by broth microdilution method
AID1761369	Antibacterial activity against clinical isolate Escherichia coli 718 measured after 24 hrs by broth microdilution method
AID1761355	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 713 measured after 24 hrs by broth microdilution method
AID1761359	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1065 measured after 24 hrs by broth microdilution method
AID1761341	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by broth microdilution method
AID1684395	Antibacterial activity against Staphylococcus epidermidis assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684376	Bactericidal activity against Klebsiella pneumoniae ATCC 1813 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684363	Antibacterial activity against methicillin- resistant Staphylococcus aureus 2020 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684397	Antibacterial activity against Klebsiella pneumoniae ATCC 1813 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684375	Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761344	Cytotoxicity against human skin fibroblasts assessed as cell viability measured after 72 hrs by MTT assay
AID1684358	Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 1 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684359	Antibacterial activity against methicillin- resistant Moraxella sp.829 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761368	Antibacterial activity against clinical isolate Proteus sp. 17 measured after 24 hrs by broth microdilution method
AID1761339	Antibacterial activity against Micrococcus luteus clinical isolate measured after 24 hrs by broth microdilution method
AID1684365	Antibacterial activity against methicillin- resistant Staphylococcus aureus 983 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684360	Antibacterial activity against methicillin- resistant Moraxella sp.765 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761357	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1053 measured after 24 hrs by broth microdilution method
AID1761361	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus intermedius 1143 measured after 24 hrs by broth microdilution method
AID1761360	Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1131 measured after 24 hrs by broth microdilution method
AID1684377	Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761336	Antibacterial activity against clinical isolate Staphylococcus ureilyticus 1972 measured after 24 hrs by broth microdilution method
AID1761393	Lipophilicity, logP of the compound
AID1684380	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684370	Selectivity index, ratio of CC50 for human HSF cells to MIC for Escherichia coli ATCC 25922	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684373	Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus aureus ATCC 29213	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761378	Antibacterial activity against Staphylococcus aureus assessed as fold increase in MIC after 8 passages by serial dilution method
AID1684378	Bactericidal activity against Bacillus subtilis 168 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684356	Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 5 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684396	Antibacterial activity against Bacillus subtilis 168 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684368	Selectivity index, ratio of CC50 for human HSF cells to MIC for Pseudomonas aeruginosa ATCC 27853	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761365	Antibacterial activity against clinical isolate Acinetobacter sp. 3 measured after 24 hrs by broth microdilution method
AID1684367	Antibacterial activity against methicillin- resistant Staphylococcus haemolyticus 837 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684371	Selectivity index, ratio of CC50 for human HSF cells to MIC for Bacillus subtilis 168	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761370	Antibacterial activity against clinical isolate Moraxella 765 measured after 24 hrs by broth microdilution method
AID1761367	Antibacterial activity against clinical isolate Klebsiella sp. 11 measured after 24 hrs by broth microdilution method
AID1761338	Antibacterial activity against Bacillus subtilis 168 measured after 24 hrs by broth microdilution method
AID1684361	Antibacterial activity against methicillin- resistant Moraxella sp.764 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (3.23)	18.7374
1990's	8 (25.81)	18.2507
2000's	8 (25.81)	29.6817
2010's	8 (25.81)	24.3611
2020's	6 (19.35)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	46.04 (24.57)
Research Supply Index	3.74 (2.92)
Research Growth Index	5.36 (4.65)
Search Engine Demand Index	101.79 (26.88)
Search Engine Supply Index	3.02 (0.95)

This Compound (46.04)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.50%)	5.53%
Reviews	2 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (2.50%)	0.25%
Other	36 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cetylpyridinium Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.	7.11	1	0	pyridinium ion
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.39	1	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.04	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
molybdenum disulfide [no description available]	7.6	1	0	sulfide salt
molybdenum Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.	7.6	1	0	chromium group element atom	micronutrient
octenidine [no description available]	2.41	1	0	dihydropyridine
decamethoxine decamethoxine: structure	2.63	2	0	quaternary ammonium salt
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	2	1	0
calixarenes Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.	2.31	1	0
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	1.97	1	0	organic sodium salt	detergent; protein denaturant
alpha-chymotrypsin Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.	2.04	1	0
alprostadil [no description available]	3.39	1	1	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
bacteriochlorophylls Bacteriochlorophylls: Pyrrole containing pigments found in photosynthetic bacteria.	2.41	1	0
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	2.76	2	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2.06	1	0	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen

Condition	Relationship Strength	Studies	Trials
Bacterial Conjunctivitides [description not available]	2.08	1	0
Conjunctivitis, Bacterial Purulent infections of the conjunctiva by several species of gram-negative, gram-positive, or acid-fast organisms. Some of the more commonly found genera causing conjunctival infections are Haemophilus, Streptococcus, Neisseria, and Chlamydia.	2.08	1	0
HIV Coinfection [description not available]	3	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3	1	0
Diabetic Feet [description not available]	3.83	2	1
Complications of Diabetes Mellitus [description not available]	2.1	1	0
Ache [description not available]	2.1	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.1	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.1	1	0
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	8.83	2	1
Infection, Wound [description not available]	2.43	2	0
Chronic Illness [description not available]	2.93	4	0
Diseases of Nasopharynx [description not available]	2.04	1	0
Infection [description not available]	2.04	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.93	4	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.04	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	2.04	1	0
Laryngitis Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.	2.04	1	0
Tonsillitis Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.	2.44	2	0
Bacterial Disease [description not available]	2.02	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	2.02	1	0
Phlegmon [description not available]	7.03	1	0
Jaw Diseases Diseases involving the JAW.	2.03	1	0
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	2.03	1	0
Pus [description not available]	2.69	3	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	1.99	1	0
Abscess, Pulmonary [description not available]	1.99	1	0
Empyema, Thoracic [description not available]	1.99	1	0
Bronchiectasis Persistent abnormal dilatation of the bronchi.	1.99	1	0
Lung Abscess Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.	1.99	1	0
Empyema, Pleural Suppurative inflammation of the pleural space.	1.99	1	0
Infection, Postoperative Wound [description not available]	2.4	2	0
Abscess, Abdominal [description not available]	2	1	0
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	2	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	3.39	1	1
Acute Bacterial Prostatitis [description not available]	1.97	1	0
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	6.97	1	0
Urethritis Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both.	1.97	1	0

chemdatabank.com